Dana Walters, Ph.D.

MSL
BridgeBio Pharma, Inc.

Poster(s):

• (T1130-05-32) Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients with Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
  Tuesday, November 11, 2025

  11:30 AM - 12:30 PM CT

• (T1230-05-32) Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants with Transthyretin Amyloid Cardiomyopathy Compared with Placebo, Independent of Atrial Fibrillation Status
  Tuesday, November 11, 2025

  12:30 PM - 1:30 PM CT

• (M1230-05-33) Serum Transthyretin Levels at Day 28 are Associated with Cardiovascular Outcomes: Insights from the ATTRibute-CM Study
  Monday, November 10, 2025

  12:30 PM - 1:30 PM CT